We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » BMS’ Opdivo Bags Another Lung Cancer Indication From FDA
BMS’ Opdivo Bags Another Lung Cancer Indication From FDA
The FDA Friday approved a third indication for Bristol-Myers Squibb’s Opdivo, this time to treat metastatic non-squamous non-small cell lung cancer that has progressed during or after platinum-based chemotherapy.